# Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06613009/  
OnCo record `nct06613009` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of IBI3009 in unresectable, metastatic or extensive-stage small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.

## Summary

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer is a phase 1 interventional study registered as NCT06613009 by Innovent Biologics (Suzhou) Co. Ltd.; 190 participants are planned, it started on 2024-12-30; the registry gives 2027-08-30 as its primary completion date. Interventions recorded: IBI3009. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06613009
- Phase: 1
- Setting: A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT06613009: https://clinicaltrials.gov/study/NCT06613009

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [IBI3009](https://onco.cc/drugs/ibi3009/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)

---
JSON: https://onco.cc/api/v1/entities/nct06613009.json